Skip to content
This randomised control trial aims to determine whether early commencement of a sequential schedule of two pneumococcal conjugate vaccines, Pneumococcal Haemophilus influenzae protein D-conjugate vaccine (PHiD-CV or Synflorix) and 13-valent pneumococcal conjugate vaccine (PCV13 or Prevenar13), given in sequence at one, two, four (PHiD-CV), and 6 months (PCV13), gives greater protection against otitis media compared to either PCV13-alone or PHiD-CV-alone at two, four, and six months.
The project also aims to determine if a combination of pneumococcal vaccines is superior to single vaccines in terms of immunogenicity, nasopharyngeal carriage of otitis media pathogens and all-cause otitis media in Aboriginal and Torres trait Islander infants living in remote communities.
The project is funded by the National Health and Medical Research Council (NHMRC) and headed by Menzies School of Health Research.
Professor Amanda Leach
Menzies School of Health Research
John Mathews Building (JMB)
Building 58, Royal Darwin Hospital Campus
Tiwi NT 0810
PO Box 41096
Casuarina NT 0811